{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T04:57:58Z","timestamp":1785560278766,"version":"3.56.0"},"reference-count":40,"publisher":"Japanese Society of Internal Medicine","issue":"15","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026,8,1]]},"DOI":"10.2169\/internalmedicine.6548-25","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T22:07:49Z","timestamp":1766009269000},"page":"2015-2023","source":"Crossref","is-referenced-by-count":1,"title":["Verification of the Short-term Effect of SGLT2 Inhibitors on Serum Magnesium Stratified by the Classification of Albuminuria Severity in Patients with Type 2 Diabetes Mellitus"],"prefix":"10.2169","volume":"65","author":[{"given":"Takashi","family":"Kitao","sequence":"first","affiliation":[{"name":"Department of Cardiology, Minoh City Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eriko","family":"Konishi","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Minoh City Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motohiro","family":"Kubori","sequence":"additional","affiliation":[{"name":"Department of Diabetes\/Endocrinology and Metabolism, Minoh City Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshio","family":"Komoda","sequence":"additional","affiliation":[{"name":"Department of Diabetes\/Endocrinology and Metabolism, Minoh City Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiko","family":"Mori","sequence":"additional","affiliation":[{"name":"Department of Diabetes\/Endocrinology and Metabolism, Minoh City Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Ibata","sequence":"additional","affiliation":[{"name":"Department of Diabetes\/Endocrinology and Metabolism, Minoh City Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. de Baaij JH, Hoenderop JG, Bindels RJ. Magnesium in man: implications for health and disease. Physiol Rev 95: 1-46, 2015.","DOI":"10.1152\/physrev.00012.2014"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Howard AB, Alexander RW, Taylor WR. Effects of magnesium on nitric oxide synthase activity in endothelial cells. Am J Physiol 269: 612-618, 1995.","DOI":"10.1152\/ajpcell.1995.269.3.C612"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Mazur A, Maier JA, Rock E, Gueux E, Nowacki W, Rayssiguier Y. Magnesium and the inflammatory response: potential physiopathological implications. Arch Biochem Biophys 458: 48-56, 2007.","DOI":"10.1016\/j.abb.2006.03.031"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Ankush RD, Suryakar AN, Ankush NR. Hypomagnesaemia in type-2 diabetes mellitus patients: a study on the status of oxidative and nitrosative stress. Indian J Clin Biochem 24: 184-189, 2009.","DOI":"10.1007\/s12291-009-0033-y"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Ma J, Folsom AR, Melnick SL, et al. Associations of serum and dietary magnesium with cardiovascular disease, hypertension, diabetes, insulin, and carotid arterial wall thickness: the ARIC study. Atherosclerosis Risk in Communities Study. J Clin Epidemiol 48: 927-940, 1995.","DOI":"10.1016\/0895-4356(94)00200-A"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Pham PC, Pham PM, Pham PA, et al. Lower serum magnesium levels are associated with more rapid decline of renal function in patients with diabetes mellitus type 2. Clin Nephrol 63: 429-436, 2005.","DOI":"10.5414\/CNP63429"},{"key":"7","doi-asserted-by":"publisher","unstructured":"7. Sakaguchi Y, Shoji T, Hayashi T, et al. Hypomagnesemia in type 2 diabetic nephropathy: a novel predictor of end-stage renal disease. Diabetes Care 35: 1591-1597, 2012.","DOI":"10.2337\/dc12-0226"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Lutsey PL, Alonso A, Michos ED, et al. Serum magnesium, phosphorus, and calcium are associated with risk of incident heart failure: the Atherosclerosis Risk in Communities (ARIC) Study. Am J Clin Nutr 100: 756-764, 2014.","DOI":"10.3945\/ajcn.114.085167"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Khan AM, Lubitz SA, Sullivan LM, et al. Low serum magnesium and the development of atrial fibrillation in the community: the Framingham Heart Study. Circulation 127: 33-38, 2013.","DOI":"10.1161\/CIRCULATIONAHA.111.082511"},{"key":"10","doi-asserted-by":"publisher","unstructured":"10. Adebamowo SN, Jim\u00e9nez MC, Chiuve SE, Spiegelman D, Willett WC, Rexrode KM. Plasma magnesium and risk of ischemic stroke among women. Stroke 45: 2881-2886, 2014.","DOI":"10.1161\/STROKEAHA.114.005917"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Kieboom BC, Niemeijer MN, Leening MJ, et al. Serum magnesium and the risk of death from coronary heart disease and sudden cardiac death. J Am Heart Assoc 5: e002707, 2016.","DOI":"10.1161\/JAHA.115.002707"},{"key":"12","doi-asserted-by":"publisher","unstructured":"12. Sun X, Zhuang X, Huo M, et al. Serum magnesium and the prevalence of peripheral artery disease: the Atherosclerosis Risk in Communities (ARIC) study. Atherosclerosis 282: 196-201, 2019.","DOI":"10.1016\/j.atherosclerosis.2018.12.004"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Corsonello A, Ientile R, Buemi M, et al. Serum ionized magnesium levels in type 2 diabetic patients with microalbuminuria or clinical proteinuria. Am J Nephrol 20: 187-192, 2000.","DOI":"10.1159\/000013582"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Lu J, Gu Y, Guo M, Chen P, Wang H, Yu X. Serum magnesium concentration is inversely associated with albuminuria and retinopathy among patients with diabetes. J Diabetes Res 2016: 1260141, 2016.","DOI":"10.1155\/2016\/1260141"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Eker ES, Atao\u011flu HE. The relationship between hypomagnesemia and albuminuria in patients with type 2 diabetes mellitus. Clin Endocrinol 101: 216-222, 2024.","DOI":"10.1111\/cen.15094"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Feng C, Wu M, Chen Z, et al. Effect of SGLT2 inhibitor on renal function in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. Int Urol Nephrol 51: 655-669, 2019.","DOI":"10.1007\/s11255-019-02112-6"},{"key":"17","doi-asserted-by":"publisher","unstructured":"17. Tang H, Zhang X, Zhang J, et al. Elevated serum magnesium associated with SGLT2 inhibitor use in type 2 diabetes patients: a meta-analysis of randomised controlled trials. Diabetologia 59: 2546-2551, 2016.","DOI":"10.1007\/s00125-016-4101-6"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int 105: S117-S314, 2024.","DOI":"10.1016\/j.kint.2023.10.018"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Gilbert RE, Mende C, Vijapurkar U, Sha S, Davies MJ, Desai M. Effects of canagliflozin on serum magnesium in patients with type 2 diabetes mellitus: a post hoc analysis of randomized controlled trials. Diabetes Ther 8: 451-458, 2017.","DOI":"10.1007\/s13300-017-0232-0"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Toto RD, Goldenberg R, Chertow GM, et al. Correction of hypomagnesemia by dapagliflozin in patients with type 2 diabetes: a post hoc analysis of 10 randomized, placebo-controlled trials. J Diabetes Complications 33: 107402, 2019.","DOI":"10.1016\/j.jdiacomp.2019.06.007"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Zhang J, Huan Y, Leibensperger M, Seo B, Song Y. Comparative effects of sodium-glucose cotransporter 2 inhibitors on serum electrolyte levels in patients with type 2 diabetes: a pairwise and network meta-analysis of randomized controlled trials. Kidney360 3: 477-487, 2022.","DOI":"10.34067\/KID.0006672021"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Osawa K, Ohya M, Yamamoto S, et al. SGLT2 inhibitors increase low serum magnesium levels in patients with chronic kidney disease immediately after treatment. Clin Exp Nephrol 29: 452-459, 2025.","DOI":"10.1007\/s10157-024-02590-8"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Sasaki Y, Koyano K, Iida S, Yanagawa T. Mechanism underlying increase of the serum magnesium concentration observed following treatment with sodium-glucose cotransporter 2 inhibitors. J Diabetes Mellitus 7: 241-248, 2017.","DOI":"10.4236\/jdm.2017.74019"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Curry JN, Yu ASL. Magnesium handling in the kidney. Adv Chronic Kidney Dis 25: 236-243, 2018.","DOI":"10.1053\/j.ackd.2018.01.003"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Takayanagi K, Shimizu T, Tayama Y, et al. Downregulation of transient receptor potential M6 channels as a cause of hypermagnesiuric hypomagnesemia in obese type 2 diabetic rats. Am J Physiol Renal Physiol 308: F1386-F1397, 2015.","DOI":"10.1152\/ajprenal.00593.2013"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Figueres L, Bruneau S, Prot-Bertoye C, et al. Hypomagnesemia, hypocalcemia, and tubulointerstitial nephropathy caused by claudin-16 autoantibodies. J Am Soc Nephrol 33: 1402-1410, 2022.","DOI":"10.1681\/ASN.2022010060"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Liu D, Lv LL. New understanding on the role of proteinuria in progression of chronic kidney disease. Adv Exp Med Biol 1165: 487-500, 2019.","DOI":"10.1007\/978-981-13-8871-2_24"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Oka T, Hamano T, Sakaguchi Y, et al. Proteinuria-associated renal magnesium wasting leads to hypomagnesemia: a common electrolyte abnormality in chronic kidney disease. Nephrol Dial Transplant 34: 1154-1162, 2019.","DOI":"10.1093\/ndt\/gfy119"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Shah CV, Sparks MA, Lee CT. Sodium\/glucose cotransporter 2 inhibitors and magnesium homeostasis: a review. Am J Kidney Dis 83: 648-658, 2024.","DOI":"10.1053\/j.ajkd.2023.11.006"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Terashita M, Yazawa M, Murakami N, Nishiyama A; Electrolyte Winter Seminar Collaborative Group. Water and electrolyte abnormalities in novel pharmacological agents for kidney disease and cancer. Clin Exp Nephrol 29: 521-533, 2025.","DOI":"10.1007\/s10157-025-02635-6"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Ng HY, Kuo WH, Tain YL, Leung FF, Lee WC, Lee CT. Effect of dapagliflozin and magnesium supplementation on renal magnesium handling and magnesium homeostasis in metabolic syndrome. Nutrients 13: 4088, 2021.","DOI":"10.3390\/nu13114088"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Sato S, Takayanagi K, Shimizu T, Kanozawa K, Iwashita T, Hasegawa H. Correlation between albuminuria and interstitial injury marker reductions associated with SGLT2 inhibitor treatment in diabetic patients with renal dysfunction. Eur J Med Res 27: 140, 2022.","DOI":"10.1186\/s40001-022-00737-5"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Seino Y, Yabe D, Sasaki T, Fukatsu A, et al. Sodium-glucose cotransporter-2 inhibitor luseogliflozin added to glucagon-like peptide 1 receptor agonist liraglutide improves glycemic control with bodyweight and fat mass reductions in Japanese patients with type 2 diabetes: a 52-week, open-label, single-arm study. J Diabetes Investig 9: 332-340, 2018.","DOI":"10.1111\/jdi.12694"},{"key":"34","doi-asserted-by":"publisher","unstructured":"34. Llorens-Cebri\u00e0 C, Molina-Van den Bosch M, Vergara A, Jacobs-Cach\u00e1 C, Soler MJ. Antioxidant roles of SGLT2 inhibitors in the kidney. Biomolecules 12: 143, 2022.","DOI":"10.3390\/biom12010143"},{"key":"35","doi-asserted-by":"publisher","unstructured":"35. Paolisso G, Sgambato S, Passariello N, et al. Insulin induces opposite changes in plasma and erythrocyte magnesium concentrations in normal man. Diabetologia 29: 644-647, 1986.","DOI":"10.1007\/BF00869264"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Pham PC, Pham PM, Pham SV, Miller JM, Pham PT. Hypomagnesemia in patients with type 2 diabetes. Clin J Am Soc Nephrol 2: 366-373, 2007.","DOI":"10.2215\/CJN.02960906"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Niranjan S, Phillips BE, Giannoukakis N. Uncoupling hepatic insulin resistance - hepatic inflammation to improve insulin sensitivity and to prevent impaired metabolism-associated fatty liver disease in type 2 diabetes. Front Endocrinol (Lausanne) 14: 1193373, 2023.","DOI":"10.3389\/fendo.2023.1193373"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Mirarchi L, Amodeo S, Citarrella R, Licata A, Soresi M, Giannitrapani L. SGLT2 inhibitors as the most promising influencers on the outcome of non-alcoholic fatty liver disease. Int J Mol Sci 23: 3668, 2022.","DOI":"10.3390\/ijms23073668"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Sano M. Sodium glucose cotransporter (SGLT)-2 inhibitors alleviate the renal stress responsible for sympathetic activation. Ther Adv Cardiovasc Dis 14: 1753944720939383, 2020.","DOI":"10.1177\/1753944720939383"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Pickering G, Mazur A, Trousselard M, et al. Magnesium status and stress: the vicious circle concept revisited. Nutrients 12: 3672, 2020.","DOI":"10.3390\/nu12123672"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/15\/65_6548-25\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T04:13:56Z","timestamp":1785557636000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/15\/65_6548-25\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,1]]},"references-count":40,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.6548-25","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,1]]},"article-number":"6548-25"}}